Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Biol Psychiatry. 2014 Jul 28;79(5):362–371. doi: 10.1016/j.biopsych.2014.07.019

Figure 1. L-DOPA-induced dyskinesia is reduced in mitogen- and stress-activated kinase 1 knock out (MSK1 KO) mice.

Figure 1

Wild-type and MSK1 KO mice received unilateral injections of 6-hydroxydopamine (6-OHDA) and were treated for 9 days with L-DOPA. A, Time profile of total abnormal involuntary movements (AIMs) scored for 1 min every 20 min over a period of 120 min after the last administration of L-DOPA. Repeated measures ANOVA revealed a significant effect of genotype (p < 0.05). B, Sum of total AIMs scored during all observation periods. * p < 0.05 vs. wild-type littermates. C, Sums of AIM subscores (axial, limb and orofacial) scored during all observation periods. ** p < 0.01 vs. wild-type littermates. D, Left forelimb use determined by the cylinder test in 6-OHDA lesioned wild-type and MSK1 KO mice before (left) and after (right) administration of L-DOPA. * p < 0.05 vs. 6-OHDA lesioned without L-DOPA. All data are shown as means ± SEM.

HHS Vulnerability Disclosure